Dr. Gary D. Lopaschuk

Degrees
BSc, University of British Columbia, Canada
PhD, University of British Columbia, Canada
Current position
Scientific Director, Mazankowski Alberta Heart Institute, University of Alberta
Distinguished University Professor, Departments of Pediatrics and Pharmacology, University of Alberta
Alberta Heritage Foundation for Medical Research Scientist

Appointments
Project Leader, CFI “Cardiovascular Translational Research Centre”
Director of Research, Department of Pediatrics, University of Alberta
BioAlberta Leadership in Science & Innovation Award
Canadian Cardiovascular Society Research Achievement Award
Medical Advisory Board, Heart and Stroke Foundation of Alberta, N.W.T. and Nunavut, member
Chair, Personal Program Review Task Force, Heart and Stroke Foundation of Canada
NIH “Metabolism and Myocardial Ischemia” Study Section, Member
Chairman, Scientific Review Committee, Heart and Stroke Foundation of Alberta
Editorial Board, Circulation Research
Editorial Board, J Clinical Investigation
Associate Editor, Americal Journal of Physiology, Heart
Associate Editor, Canadian Journal of Physiology and Pharmacology
Editorial Board, Cardiovascular Research
Editorial Board, Basic Research in Cardiology
Scientific Advisory Committee, Women’s and Children’s Health Research Institute

Consulting experience
Extensive consulting track record with pharma and named on hundreds of patents.

Biography
Dr. Gary D. Lopaschuk is a Distinguished University Professor of Pediatrics at the University of Alberta, Edmonton. He is a Cardiovascular Researcher whose research focuses on the regulation of fatty acid oxidation in the heart, and the mechanism by which high rates of fatty acid oxidation contribute to heart disease and heart failure. He is also examining how alterations in fatty acid metabolism contribute to cardiovascular disease in the diabetic. At a molecular level he has characterized a number of key enzymes important in the regulation of cardiac fatty acid oxidation. He is also developing a number of therapeutic strategies that involve optimizing energy metabolism in the heart that can be used to prevent the development of heart disease, and that can also be used to treat heart failure. His research has resulted in the publication of over 330 original research articles, and he has been recognized by awards such as the Canadian Cardiovascular Research Achievement Award and the International Academy of Cardiovascular Sciences Research Achievement Award.

Dr. Lopaschuk is an Alberta Innovates Health Solution Scientist, and is a Fellow of the Royal Society of Canada. He serves on a number of journal editorial boards, including Circulation Research, Journal of Clinical Investigation, American Journal of Physiology, Cardiovascular Research, Journal of Molecular and Cellular Cardiology, Canadian Journal of Physiology and Pharmacology, Heart and Metabolism, and Cardiovascular Drugs and Therapy. He is also the President and CEO of a biotechnology company (Metabolic Modulators Research Ltd.), that is developing novel drugs to treat heart disease that optimize energy metabolism in the heart.